Briacell Therapeutics Corp (NASDAQ: BCTX) Collaborative Advanced Breast Cancer Trial Open for Enrollment

Briacell Therapeutics Corp (NASDAQ: BCTX) announced that recruitment and enrolment are open for its advanced breast cancer trial. The company is performing the study in partnership with Incyte. The Phase I/IIa combination study is designed to evaluate BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitor, retifanlimab, and IDO1 inhibitor, epacadostat, for the treatment of advanced breast cancer.

Incyte to provide compounds from its development portfolio

The Briacell Therapeutics Corp and Incyte clinical program is a non-exclusive clinical trial collaboration. The trial aims to evaluate the effects of combinations of novel clinical candidates. As part of the agreement, Incyte will provide compounds from its development portfolio, including retifanlimab, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor. The compounds will be used in combination studies with Bria-IMT™, in advanced breast cancer patients.

Success stories scripted in the past

In a collaborative effort, both Briacell Therapeutics Corp and Incyte have treated two patients under Phase I/IIa. The two patients were treated before the corporate collaboration commencement in April 2019. In addition, Briacell Therapeutics Corp recently made an official survival data announcement. The list included the names of some of the patients. Having funds in hand, the company has declared open enrolment for its latest study. 

“We are aligned with our clinical collaboration partners at Incyte in placing value on innovation and look forward to further developing novel therapeutics for advanced breast cancer patients together,” stated Dr. Bill Williams, BriaCell’s President, and CEO. “Our preliminary data indicates that this novel combination has the potential to be a safe and effective treatment for advanced breast cancer patients who have few to no other treatment options.”

Briacell Therapeutics Corp is a clinical-stage biotechnology company. The team of specialists at the immuno-oncology biotechnology company is focused on developing targeted and practical approaches for cancer management. According to data provided by the website, one in every eight women in the U.S. suffers from breast cancer. More women are diagnosed with breast cancer than any other type of cancer, besides skin cancer, the website brings to light.

Leave a Comment

Your email address will not be published.